Human Genome maintained by Merrill at neutral

Human Genome Sciences, Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating after the company announced plans to spin out CoGenesys as a separate entity. Human Genome will give it $10 million and it will seek external funding. Human Genome's equity position remains unclear and depends on management's ability to secure external funding. The identity of the products to be spun out to CoGenesys also has not been disclosed. Shares of the Rockville, Md., biopharmaceutical company were down 10 cents, or 1.11%, at $8.91 on volume of 1,901,768 shares versus the three-month running average of 3,627,030 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.